FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to hematology, and can be used in the treatment of thrombocytopenia in coronavirus infection. A method for the treatment of patients with moderate and severe forms of coronavirus infection with concomitant immune thrombocytopenia (ITP) includes drug therapy, while using levilimab at a dose of 324 mg once as two injections of 162 mg each subcutaneously in combination with methylprednisolone 0.8-1.0 mg/kg/day for 5 days and intravenous administration of polyvalent immunoglobulin at a dose of 0.4-0.5 g/kg/day drip for 5 days.
EFFECT: use of the method provides an increase in the effectiveness of treatment of patients with ITP associated with moderate and severe forms of the course of COVID-19.
1 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
| METHOD FOR TREATMENT OF NEW CORONAVIRUS INFECTION | 2022 |
|
RU2790939C1 |
| METHOD FOR COVID-19 PNEUMONIA TREATMENT | 2020 |
|
RU2745535C1 |
| METHOD FOR PERSONIFIED PREDICTION OF FATAL OUTCOMES OF COVID-19-ASSOCIATED PNEUMONIA IN ELDERLY AND SENILE PATIENTS | 2023 |
|
RU2817106C1 |
| METHOD FOR PREDICTION OF OUTCOME OF VIRAL PNEUMONIA IN COVID-19 | 2021 |
|
RU2764002C1 |
| METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
| METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
| METHOD FOR TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH SARS-CoV-2 | 2021 |
|
RU2780939C1 |
| METHOD FOR DIAGNOSING SEVERE PSEUDOMEMBRANOUS COLITIS IN PATIENTS AFTER CORONAVIRUS INFECTION | 2022 |
|
RU2786752C1 |
| METHOD FOR ASSESSING UNFAVORABLE OUTCOME OF SEVERE PNEUMONIA ASSOCIATED WITH COVID-19 BY s-CysC LEVEL | 2022 |
|
RU2779581C2 |
